Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells

Biochimie

Volumn 94, Issue 11, 2012, Pages 2308-2313

  Valente, Sergio ^a   Lepore, Ilaria ^b   Dell'Aversana, Carmela ^b,c   Tardugno, Maria ^a,d   Castellano, Sabrina ^d   Sbardella, Gianluca ^d   Tomassi, Stefano ^e   Di Maro, Salvatore ^e   Novellino, Ettore ^e   Di Santo, Roberto ^a   Costi, Roberta ^a   Altucci, Lucia ^b,c   Mai, Antonello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bis(bromo and dibromo phenol) compounds; Epi drugs; Epigenetics; Histone methylation; Leukemia

Indexed keywords

1,5 BIS(3 BROMO 4 METHOXYPHENYL)PENTA 1,4 DIEN 3 ONE; 2,6 BIS(3 BROMO 4 METHOXYBENZYLIDENE)CYCLOHEXANONE; 2,6 BIS(3,5 DIBROMO 4 METHOXYBENZYLIDENE)CYCLOHEXANONE; BIS(3,5 DIBROMO 4 HYDROXYPHENYL)METHANONE; METHYLTRANSFERASE INHIBITOR; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G1 PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL STRAIN U937; ENZYMATIC ASSAY; ENZYME INHIBITION; EPIGENETICS; GRANULOCYTE; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; WESTERN BLOTTING;

CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GRANULOCYTES; HISTOCOMPATIBILITY ANTIGENS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; LEUKEMIA; METHYLATION; POLYCOMB REPRESSIVE COMPLEX 2; SUBSTRATE SPECIFICITY;

EID: 84867395419     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2012.06.003     Document Type: Article

References (30)

1. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
2. G.G. Wang, C.D. Allis, and P. Chi Chromatin remodeling and cancer, Part I: covalent histone modifications Trends Mol. Med. 13 2007 363 372
3. P. Chi, C.D. Allis, and G.G. Wang Covalent histone modifications- miswritten, misinterpreted and mis-erased in human cancers Nat. Rev. Cancer 10 2010 457 469
4. L.S. Kristensen, H.M. Nielsen, and L.L. Hansen Epigenetics and cancer treatment Eur. J. Pharmacol. 625 2009 131 142
5. A. Mai, and L. Altucci Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead Int. J. Biochem. Cell Biol. 41 2009 199 213
6. M. Albert, and K. Helin Histone methyltransferases in cancer Semin. Cell Dev. Biol. 21 2010 209 220
7. A. Mai Small-molecule chromatin-modifying agents: therapeutic applications Epigenomics 2 2010 307 324
8. D. Rotili, and A. Mai Targeting histone demethylases: a new avenue for the fight against cancer Genes Cancer 2 2011 663 679
9. D. Cheng, N. Yadav, R.W. King, M.S. Swanson, E.J. Weinstein, and M.T. Bedford Small molecule regulators of protein arginine methyltransferases J. Biol. Chem. 279 2004 23892 23899
10. R. Ragno, S. Simeoni, S. Castellano, C. Vicidomini, A. Mai, A. Caroli, A. Tramontano, C. Bonaccini, P. Trojer, I. Bauer, G. Brosch, and G. Sbardella Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations J. Med. Chem. 50 2007 1241 1253
11. S. Castellano, C. Milite, R. Ragno, S. Simeoni, A. Mai, V. Limongelli, E. Novellino, I. Bauer, G. Brosch, A. Spannhoff, D. Cheng, M.T. Bedford, and G. Sbardella Design, synthesis and biological evaluation of carboxy analogues of arginine methyltransferase inhibitor 1 (AMI-1) ChemMedChem 5 2010 398 414
12. A. Mai, S. Valente, D. Cheng, A. Perrone, R. Ragno, S. Simeoni, G. Sbardella, G. Brosch, A. Nebbioso, M. Conte, L. Altucci, and M.T. Bedford Synthesis and biological validation of novel synthetic histone/protein methyltransferase inhibitors ChemMedChem 2 2007 987 991
13. R. Costi, R. Di Santo, M. Artico, G. Miele, P. Valentini, E. Novellino, and A. Cereseto Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase J. Med. Chem. 50 2007 1973 1977
14. A. Mai, D. Cheng, M.T. Bedford, S. Valente, A. Nebbioso, A. Perrone, G. Brosch, G. Sbardella, F. De Bellis, M. Miceli, and L. Altucci Epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors J. Med. Chem. 51 2008 2279 2290
15. D. Cheng, S. Valente, S. Castellano, G. Sbardella, R. Di Santo, R. Costi, M.T. Bedford, and A. Mai Novel 3,5-bis(bromohydroxybenzylidene)piperidin-4-ones as coactivator-associated arginine methyltransferase 1 inhibitors: enzyme selectivity and cellular activity J. Med. Chem. 54 2011 4928 4932
16. K. Nishioka, J.C. Rice, K. Sarma, H. Erdjument-Bromage, J. Werner, Y. Wang, S. Chuikov, P. Valenzuela, P. Tempst, R. Steward, J.T. Lis, C.D. Allis, and D. Reinberg PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin Mol. Cell 9 2002 1201 1213
17. S. Wu, and J.C. Rice A new regulator of the cell cycle: the PR-Set7 histone methyltransferase Cell Cycle 10 2011 68 72
18. D. Patnaik, H.G. Chin, P.O. Esteve, J. Benner, S.E. Jacobsen, and S. Pradhan Substrate specificity and kinetic mechanism of mammalian G9a histone H3 methyltransferase J. Biol. Chem. 279 2004 53248 53258
19. M.W. Chen, K.T. Hua, H.J. Kao, C.C. Chi, L.H. Wei, G. Johansson, S.G. Shiah, P.S. Chen, Y.M. Jeng, T.Y. Cheng, T.C. Lai, J.S. Chang, Y.H. Jan, M.H. Chien, C.J. Yang, M.S. Huang, M. Hsiao, and M.L. Kuo H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM Cancer Res. 70 2010 7830 7840
20. K. Nishioka, S. Chuikov, K. Sarma, H. Erdjument-Bromage, C.D. Allis, P. Tempst, and D. Reinberg Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation Genes Dev. 16 2002 479 489
21. Y. Li, M.A. Reddy, F. Miao, N. Shanmugam, J.K. Yee, D. Hawkins, B. Ren, and R. Natarajan Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation J. Biol. Chem. 283 2008 26771 26781
22. L.E. Surface, S.R. Thornton, and L.A. Boyer Polycomb group proteins set the stage for early lineage commitment Cell Stem Cell 7 2010 288 298
23. M. Sauvageau, and G. Sauvageau Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer Cell Stem Cell 7 2010 299 313
24. D.P. Tsang, and A.S. Cheng Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2 J. Gastroenterol. Hepatol. 26 2011 19 27
25. C.G. Kleer, Q. Cao, S. Varambally, R. Shen, I. Ota, S.A. Tomlins, D. Ghosh, R.G. Sewalt, A.P. Otte, D.F. Hayes, M.S. Sabel, D. Livant, S.J. Weiss, M.A. Rubin, and A.M. Chinnaiyan EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc. Natl. Acad. Sci. U.S.A. 100 2003 11606 11611
26. S. Varambally, S.M. Dhanasekaran, M. Zhou, T.R. Barrette, C. Kumar-Sinha, M.G. Sanda, D. Ghosh, K.J. Pienta, R.G. Sewalt, A.P. Otte, M.A. Rubin, and A.M. Chinnaiyan The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
27. J. Yu, D.R. Rhodes, S.A. Tomlins, X. Cao, G. Chen, R. Mehra, X. Wang, D. Ghosh, R.B. Shah, S. Varambally, K.J. Pienta, and A.M. Chinnaiyan A polycomb repression signature in metastatic prostate cancer predicts cancer outcome Cancer Res. 67 2007 10657 10663
28. G.H. Richter, S. Plehm, A. Fasan, S. Rossler, R. Unland, I.M. Bennani-Baiti, M. Hotfilder, D. Lowel, I. von Luettichau, I. Mossbrugger, L. Quintanilla-Martinez, H. Kovar, M.S. Staege, C. Muller-Tidow, and S. Burdach EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation Proc. Natl. Acad. Sci. U.S.A. 106 2009 5324 5329
29. J. Lee, M.J. Son, K. Woolard, N.M. Donin, A. Li, C.H. Cheng, S. Kotliarova, Y. Kotliarov, J. Walling, S. Ahn, M. Kim, M. Totonchy, T. Cusack, C. Ene, H. Ma, Q. Su, J.C. Zenklusen, W. Zhang, D. Maric, and H.A. Fine Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells Cancer Cell 13 2008 69 80
30. C. Wang, Z. Liu, C.W. Woo, Z. Li, L. Wang, J.S. Wei, V.E. Marquez, S.E. Bates, Q. Jin, J. Khan, K. Ge, and C.J. Thiele EZH2 mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3 and NGFR Cancer Res. 72 2012 315 324